Cytori Reports Fourth Quarter and Full Year 2017 Business and Financial Results

Genetics Investing

Cytori Therapeutics (NASDAQ:CYTX) announced its fourth quarter and year-end 2017 financial results and provided updates on its corporate activity and clinical development. As quoted in the press release: “Manufacturing activities for our oncology drug, ATI-0918, a generic version of Caelyx®, are ongoing and on track for submitting an application to the European Medicines Agency late in …

Cytori Therapeutics (NASDAQ:CYTX) announced its fourth quarter and year-end 2017 financial results and provided updates on its corporate activity and clinical development.

As quoted in the press release:

“Manufacturing activities for our oncology drug, ATI-0918, a generic version of Caelyx^®, are ongoing and on track for submitting an application to the European Medicines Agency late in 2018,” said Dr. Marc Hedrick, President and CEO of Cytori. “Additionally, the SCLERADEC-II trial for patients with scleroderma recently completed enrollment and enrollment in the ADRESU trial for patients with post surgical urinary incontinence should be completed soon. Both trials have read-outs later in 2018. Our meeting with the U.S. FDA on our STAR trial data results is forthcoming soon and we will provide an update thereafter on next steps related to Habeo™ Cell Therapy in the U.S.”

Click here to read the full press release.

application ati-0918 cell therapy cytori cytori therapeutics enrollment european medicines agency fda financial results generic Genetics Investing